1 / 6

Sources of Limited Access to Treatment

Explore limited access to treatment due to high costs and lack of demand. Learn about Green Light Committee policy, treatment regimen costs, and global efforts to enhance access to quality care. Discover similarities between HIV and MDR-TB treatments and the importance of evidence-based policies.

anitra
Download Presentation

Sources of Limited Access to Treatment

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Sources of Limited Access to Treatment High Cost of Treatment Lack of Demand Lack of Pilot Projects Lack of Policy Lack of Evidence

  2. Treatment Regimen Costs Standard Reference Country Cost (USA) High Income Country Average Cost Low Income Country Average Cost Green Light Committee Cost 60000 50000 40000 Per Patient Drug Cost (USD) 30000 20000 10000 0 HR HRES HRESZK Resistance Pattern Gupta, et al., Science 2001.

  3. Linking Independent Concepts ACCESS RATIONAL USE GLC POLICY

  4. Green Light Committee (GLC) • Releases preferentially-priced, quality-assured drugs • Decision process • application review • Instructions for Applying to the Green Light Committee for Access to Second-line Anti-TB Drugs • Guidelines for Establishing DOTS-Plus Pilot Projects for the Management of MDR-TB • site visit • Continual monitoring of projects • Technical assistance Gupta, et al. Trop Med Intl Health, 2001

  5. Changing Global Health Policy • New guidelines for MDR-TB treatment • Expanding DOTS framework to include MDR-TB • HIV, public-private mix • Improving allocation of financial resources • Increasing new funds for TB control • Scaling up primary health care/capacity building • Bridging equity gap • No longer whether or not to treat patients, but how to best treat patients

  6. Similarities between HIV and MDR-TB • Multidrug regimen given for extended periods with adverse events • Disproportionately affects disadvantaged • Access to drugs • Drug resistance • Laboratory requirements • Lack of standard international policy • Most experience in resource-wealthy settings

More Related